SCHEMBL863714

SCHEMBL863714

Clc1ccccc1-c1nnc2ccc(-c3ccc4[nH]ccc4c3)nn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 3/20 0.46
CCNT1 O60563 3/20 0.46
CDK9 P50750 3/20 0.46
CDK5 Q00535 3/20 0.46
DYRK1A Q13627 3/20 0.46
CDK5R1 Q15078 3/20 0.46
DYRK2 Q92630 3/20 0.46
DYRK1B Q9Y463 3/20 0.46
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
LRRK2 Q5S007 1/20 0.42
GUSB P08236 3/20 0.42
MET P08581 1/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
TRPA1 O75762 1/20 0.39
BRAF P15056 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863630 0.86 NPC1 (0.52) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL863333 0.80 GUSB (0.43) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL864043 0.78 MET (0.43) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL7084699 0.76 NPC1 (0.61) GUSBNPC1TRPA1BRAF
SCHEMBL16009418 0.69 DYRK3 (0.77) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL13745078 0.69 GUSB (0.66) GUSBNPC1
SCHEMBL11623516 0.67 BRD4 (0.51) METKDM4EHSD17B10HSD11B1
SCHEMBL2496961 0.66 MET (0.74) MET
SCHEMBL864044 0.66 CHRNA7 (0.50) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL29740190 0.66 DYRK3 (0.45) DYRK3CCNT1CDK9CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 DYRK3 3686/4885CCNT1 3623/4885CDK9 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.